Indeed, cancer cells can evade the immune-surveillance pathway by displaying a wide range of co-inhibitory components such as programmed cell death ligand-1/2 (PD-L1/2), cytotoxic T lymphocyte antigen-4 (CTLA4), T cell immune receptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), and lymphocyte activating antigen-3 (LAG-3) [10]. Here, CTLA4 is linked to cancer.